Immuno-Oncology | Specialty

Emerging Second-Line Therapies in HCC

February 23rd 2018

Frontline Clinical Trials in Liver Cancer

February 23rd 2018

Sequencing Considerations in HCC

February 23rd 2018

HCC: Nivolumab's Side Effects

February 23rd 2018

Proactive Management of TKI Side Effects in HCC

February 23rd 2018

HCC: Considerations in Toxicity Management

February 23rd 2018

Second-Line Nivolumab in Liver Cancer

February 23rd 2018

Response and Outcomes With TKIs in HCC

February 23rd 2018

HCC: Multidisciplinary Decision-Making

February 23rd 2018

Trends and Risk Factors in Liver Cancer

February 23rd 2018

Pembrolizumab Active in Thymic Carcinoma

February 22nd 2018

Pembrolizumab (Keytruda) induced responses in more than one-fifth of patients with recurrent thymic carcinoma who had progressed following 1 or more lines of chemotherapy.

Simon Shares Insight on Emerging Immunotherapy Regimens in NSCLC

February 21st 2018

George R. Simon, MD, discusses emerging advancements with immunotherapy combination strategies for patients with NSCLC.

Dr. Sonpavde on Novel Prognostic Marker for Atezolizumab in Bladder Cancer

February 20th 2018

Guru Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses a novel prognostic marker for patients with advanced bladder cancer being treated with the PD-L1 inhibitor atezolizumab (Tecentriq).

Immunotherapy Trials Offer Hope in Advanced Penile Cancer

February 20th 2018

Guru Sonpavde, MD, discusses the importance of clinical trial enrollment for patients with penile cancer.

Dr. Bellmunt on Challenges With Immunotherapy in Bladder Cancer

February 20th 2018

Joaquim Bellmunt, MD, PhD, associate professor of medicine, Harvard Medical School, director, Bladder Cancer Center, Dana-Farber Cancer Institute, discusses challenges with immunotherapy in bladder cancer.

Pembrolizumab Continues to Demonstrate Long-Term Efficacy in Melanoma

February 19th 2018

The PD-1 inhibitor pembrolizumab (Keytruda) continues to be a promising frontline immunotherapy option for patients with advanced melanoma.

Dr. Patel on the FDA Approval of Durvalumab in NSCLC

February 17th 2018

Jyoti D. Patel, MD, professor of medicine, director of thoracic oncology, the University of Chicago Medicine, discusses the FDA approval of durvalumab (Imfinzi) in patients with non

FDA Approves Durvalumab for Locally Advanced NSCLC

February 17th 2018

The FDA has approved durvalumab for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer who have not progressed following chemoradiotherapy.

Biomarkers and Novel Approaches in CRC

February 17th 2018

Reverce Study: Outcomes and Impact

February 17th 2018